Market Overview The monoclonal antibody therapy market is anticipated to reach USD 259.9 billion at a 12.7% CAGR between 2023 and 2032. The monoclonal antibody therapy market is currently experiencing unprecedented success as a result of outstanding clinical outcomes in cancer immunotherapy. The introduction of monoclonal antibodies as blockbuster medications, such as Remicade, Humira, Rituxan,...